lepetegravir/lenacapavir pacfosacil FDC

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

HIV-1-InfectionHIV-1-infection

Phase 2

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

Active, not recruitingNCT06544733

Gilead SciencesHIV-1-Infection

Start: 2024-08-20End: 2029-06-01Target: 675Updated: 2026-04-17

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

TerminatedNCT06613685

Gilead SciencesHIV-1-infection

Start: 2024-10-21End: 2026-03-16Updated: 2026-04-15